John Maraganore, Alnylam CEO (Scott Eisen/Bloomberg via Getty Images)
November 8, 2021 08:31 AM ESTUpdated 08:43 AM
Bioregnum
Cell/Gene Tx

John Maraganore steps in­to a new role at an up­start biotech as the god­fa­ther phase of his ca­reer takes shape

John Maraganore isn’t wast­ing any time shift­ing to a new post-Al­ny­lam phase in his long biotech ca­reer. Start­up wun­derkind Beam Ther­a­peu­tics has lured the …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Trump asks 'very tough hom­bre' Dr. Oz to lead MFN talks

End­points 100 biotech sur­vey: Wel­come to the sum­mer of biotech’s dis­con­tent

US warns drug­mak­ers against mis­rep­re­sent­ing cost of im­port­ed prod­ucts

About 5% of CBER and CDER left af­ter FDA staff cuts, analy­sis finds

Merus’ Phase 2 over­all sur­vival da­ta reach ‘home run’ sce­nario — an­a­lyst

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times